Weiss Multi Strategy Advisers LLC Viking Therapeutics, Inc. Transaction History

Weiss Multi Strategy Advisers LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $42,735 - $90,835	4,625 Added 2.16%	218,799 $4.07 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $778,312 - $1.14 Million	-71,274 Reduced 24.97%	214,174 $2.37 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $2.38 Million - $3.98 Million	160,549 Added 128.54%	285,448 $4.63 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $1.01 Million - $2.16 Million	124,899 New	124,899 $2.08 Million
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $76,700 - $106,300	-10,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $75,800 - $99,400	-10,000 Reduced 50.0%	10,000 $99,000
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $701,680 - $1.59 Million	-98,000 Reduced 83.05%	20,000 $153,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $320,100 - $648,450	33,000 Added 38.82%	118,000 $2.06 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $329,800 - $1.08 Million	85,000 New	85,000 $807,000

478

66.1M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.